| Trial ID: | L4378 |
| Source ID: | NCT00709917
|
| Associated Drug: |
Repaglinide
|
| Title: |
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes
|
| Acronym: |
REPAMET
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide
|
| Outcome Measures: |
Primary: Safety (number of hypoglycaemic incidents), After 10-20 weeks|HbA1C, After 10-20 weeks | Secondary: safety, After 10-20 weeks|posology, After 10-20 weeks|lifestyle, After 10-20 weeks|FBG, After 10-20 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
2171
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2007-03
|
| Completion Date: |
2008-01
|
| Results First Posted: |
|
| Last Update Posted: |
2016-03-03
|
| Locations: |
Brussels, 1070, Belgium|Luxembourg, Luxembourg
|
| URL: |
https://clinicaltrials.gov/show/NCT00709917
|
